| Arginine deprivation inhibits the Warburg effect and upregulates glutamine anaplerosis and serine biosynthesis in ASS1-deficient cancers JC Kremer, BC Prudner, SES Lange, GR Bean, MB Schultze, ... Cell reports 18 (4), 991-1004, 2017 | 136 | 2017 |
| SAR405838: a novel and potent inhibitor of the MDM2: p53 axis for the treatment of dedifferentiated liposarcoma KLJ Bill, J Garnett, I Meaux, XY Ma, CJ Creighton, S Bolshakov, ... Clinical cancer research 22 (5), 1150-1160, 2016 | 102 | 2016 |
| A metabolic synthetic lethal strategy with arginine deprivation and chloroquine leads to cell death in ASS1-deficient sarcomas GR Bean, JC Kremer, BC Prudner, AD Schenone, JC Yao, MB Schultze, ... Cell death & disease 7 (10), e2406-e2406, 2016 | 86 | 2016 |
| Diagnosis and management of malignant peripheral nerve sheath tumors: Current practice and future perspectives BC Prudner, T Ball, R Rathore, AC Hirbe Neuro-Oncology Advances 2 (Supplement_1), i40-i49, 2020 | 63 | 2020 |
| Arginine starvation and docetaxel induce c-Myc–driven HENT1 surface expression to overcome gemcitabine resistance in ASS1-negative tumors BC Prudner, R Rathore, AM Robinson, A Godec, SF Chang, WG Hawkins, ... Clinical Cancer Research 25 (16), 5122-5134, 2019 | 55 | 2019 |
| HDAC8, a potential therapeutic target for the treatment of malignant peripheral nerve sheath tumors (MPNST) G Lopez, KLJ Bill, HK Bid, D Braggio, D Constantino, B Prudner, A Zewdu, ... PLoS One 10 (7), e0133302, 2015 | 55 | 2015 |
| Liposarcoma: molecular targets and therapeutic implications KLJ Bill, L Casadei, BC Prudner, H Iwenofu, AM Strohecker, RE Pollock Cellular and molecular life sciences 73, 3711-3718, 2016 | 45 | 2016 |
| Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma R Rathore, KE Caldwell, C Schutt, CB Brashears, BC Prudner, ... Cell reports 34 (4), 2021 | 41 | 2021 |
| Propofol restores TRPV1 sensitivity via a TRPA1‐, nitric oxide synthase‐dependent activation of PKCε P Sinharoy, H Zhang, S Sinha, BC Prudner, IN Bratz, DS Damron Pharmacology Research & Perspectives 3 (4), e00153, 2015 | 18 | 2015 |
| α-Synemin localizes to the M-band of the sarcomere through interaction with the M10 region of titin BC Prudner, PS Roy, DS Damron, MA Russell FEBS letters 588 (24), 4625-4630, 2014 | 15 | 2014 |
| Malic enzyme 1 absence in synovial sarcoma shifts antioxidant system dependence and increases sensitivity to ferroptosis induction with ACXT-3102 CB Brashears, BC Prudner, R Rathore, KE Caldwell, CA Dehner, ... Clinical cancer research 28 (16), 3573-3589, 2022 | 14 | 2022 |
| miR-133a function in the pathogenesis of dedifferentiated liposarcoma PY Yu, G Lopez, D Braggio, D Koller, KLJ Bill, BC Prudner, A Zewdu, ... Cancer cell international 18, 1-10, 2018 | 13 | 2018 |
| Amino acid uptake measured by [18F] AFETP increases in response to arginine starvation in ASS1-deficient sarcomas BC Prudner, F Sun, JC Kremer, J Xu, C Huang, KKS Sai, Z Morgan, ... Theranostics 8 (8), 2107, 2018 | 7 | 2018 |
| p67/MetAP2 suppresses K-RasV12-mediated transformation of NIH3T3 mouse fibroblasts in culture and in athymic mice A Majumdar, A Ghosh, S Datta, BC Prudner, B Datta Biochemistry 49 (47), 10146-10157, 2010 | 7 | 2010 |
| A phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas. M Agulnik, NA Mohindra, MM Milhem, S Attia, SI Robinson, A Rademaker, ... Journal of clinical oncology 36 (15_suppl), 11550-11550, 2018 | 5 | 2018 |
| Yoga therapy during chemotherapy for early-stage and locally advanced breast Cancer SK Greaney, N Amin, BC Prudner, M Compernolle, LJ Sandell, SC Tebb, ... Integrative Cancer Therapies 21, 15347354221137285, 2022 | 3 | 2022 |
| Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1 A Godec, R Jayasinghe, JSA Chrisinger, B Prudner, T Ball, Y Wang, ... Neuro-oncology advances 2 (Supplement_1), i75-i84, 2020 | 1 | 2020 |
| Erratum: SAR405838: A Novel and Potent Inhibitor of the MDM2: p53 Axis for the Treatment of Dedifferentiated Liposarcoma (Clin Cancer Res (2016) 22 (1150-1160 K Lynn, J Bill, J Garnett, I Meaux, XY Ma, CJ Creighton, S Bolshakov, ... Clinical Cancer Research 28 (2), 431, 2022 | | 2022 |
| Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2: p53 Axis for the Treatment of Dedifferentiated Liposarcoma KLJ Bill, J Garnett, I Meaux, XY Ma, CJ Creighton, S Bolshakov, ... Clinical Cancer Research 28 (2), 431-431, 2022 | | 2022 |
| Disruption of cholesterol metabolism via sigma-2 ligands induces cell death in pancreatic cancer R Takchi, BC Prudner, S Vangveravong, BA VanTine, D SPitzer, ... HPB 22, S66, 2020 | | 2020 |
